Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 5.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 240,156 shares of the biopharmaceutical company’s stock after purchasing an additional 11,422 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Bristol-Myers Squibb were worth $13,290,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Bristol-Myers Squibb by 2.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock valued at $22,827,000 after buying an additional 10,456 shares during the last quarter. Integrated Investment Consultants LLC grew its holdings in shares of Bristol-Myers Squibb by 1,748.8% during the second quarter. Integrated Investment Consultants LLC now owns 63,468 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 60,035 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of Bristol-Myers Squibb by 2.8% during the second quarter. Steward Partners Investment Advisory LLC now owns 43,171 shares of the biopharmaceutical company’s stock valued at $2,389,000 after buying an additional 1,161 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of Bristol-Myers Squibb by 19.1% during the second quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock valued at $58,813,000 after buying an additional 170,360 shares during the last quarter. Finally, First Mercantile Trust Co. grew its holdings in shares of Bristol-Myers Squibb by 9.6% during the second quarter. First Mercantile Trust Co. now owns 68,918 shares of the biopharmaceutical company’s stock valued at $3,814,000 after buying an additional 6,063 shares during the last quarter. Institutional investors and hedge funds own 72.17% of the company’s stock.

A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Credit Suisse Group lifted their price objective on shares of Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a report on Friday, July 27th. BMO Capital Markets reiterated a “hold” rating and set a $47.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, June 21st. UBS Group cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 price objective for the company. in a report on Monday, May 21st. Finally, Atlantic Securities upgraded shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 price objective for the company in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $63.11.

Bristol-Myers Squibb stock opened at $60.17 on Wednesday. Bristol-Myers Squibb Co has a fifty-two week low of $49.96 and a fifty-two week high of $70.05. The stock has a market cap of $98.02 billion, a P/E ratio of 17.74, a PEG ratio of 1.51 and a beta of 1.02. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.28 and a current ratio of 1.40.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The business had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.48 billion. During the same period in the previous year, the company earned $0.74 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. research analysts anticipate that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 1st. Investors of record on Friday, July 6th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.66%. The ex-dividend date was Thursday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: Diversification For Individual Investors

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.